


**Product Name** : Lumiracoxib  
**Synonyms** : CGS-35189; CGS35189; COX 189; Lumiracoxib  
**Cat No.** : M18251  
**CAS Number** : 220991-20-8  
**Molecular Formula** : C<sub>15</sub>H<sub>13</sub>ClFNO<sub>2</sub>  
**Formula Weight** : 293.72  
**Chemical Name** : 2-((2-chloro-6-fluorophenyl)amino)-5-methylphenyl)acetic acid



**Description** : Lumiracoxib, also known as CGS 35189 and COX 189, is a COX-2 selective inhibitor non-steroidal anti-inflammatory drug, manufactured by Novartis and still sold in few countries, including Mexico, Ecuador and the Dominican Republic, under the trade name Prexige. Since its original approval, lumiracoxib has been withdrawn from the market in several countries, mostly due to its potential for causing liver failure (sometimes requiring liver transplantation). It has never been approved for use in the United States.

**Pathway** : Others  
**Target** : Other Targets  
**Receptor** : COX-1; COX-2  
**Solubility** : —  
**SMILES** : Clc2cccc(F)c2Nc1ccc(C)cc1CC(=O)O  
**Storage** : (-20°C)  
**Stability** : ≥ 2 years  
**Reference** :

1.Esser R, et al. Br J Pharmacol, 2005, 144(4), 538-550.